Genentech Patent Win Can't Halt Foreign Arbitration

Law360, New York (May 10, 2013, 5:20 PM ET) -- The Federal Circuit on Friday found that Genentech Inc. cannot block a European arbitration in which it was found to have breached a cancer drug patent license with Sanofi-Aventis Deutschland GmbH, even though the court previously determined Genentech did not violate those patents.

The Federal Circuit found in March that Genentech’s cancer drugs Rituxan and Avastin did not violate Sanofi’s patents, but it said on Friday that a previously filed European arbitration proceeding is not precluded by its prior ruling because the foreign dispute deals with...
To view the full article, register now.